The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.

<h4>Background</h4>Giant cell arteritis (GCA) and Takayasu's arteritis (TAA) are large vessel vasculitides (LVV) for which corticosteroids (CS) are the mainstay for treatment. In patients with LVV unable to tolerate CS, biological agents have been used with variable effectiveness.&l...

Full description

Bibliographic Details
Main Authors: Mohammed Osman, Christian Pagnoux, Donna M Dryden, Dale Storie, Elaine Yacyshyn
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0115026
id doaj-56d9e4bcc4884ce9a3adae0174137ece
record_format Article
spelling doaj-56d9e4bcc4884ce9a3adae0174137ece2021-03-04T08:40:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01912e11502610.1371/journal.pone.0115026The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.Mohammed OsmanChristian PagnouxDonna M DrydenDale StorieElaine Yacyshyn<h4>Background</h4>Giant cell arteritis (GCA) and Takayasu's arteritis (TAA) are large vessel vasculitides (LVV) for which corticosteroids (CS) are the mainstay for treatment. In patients with LVV unable to tolerate CS, biological agents have been used with variable effectiveness.<h4>Objective</h4>To systematically review the effectiveness and safety of biological agents in patients with LVV.<h4>Methods</h4>We searched 5 electronic databases (inception to October 2012) and conference abstracts with no language restrictions. Two reviewers independently selected studies, extracted data and assessed methodological quality. Our protocol was registered in PROSPERO.<h4>Results</h4>We included 25 studies (3 RCTs and 22 case series with ≥2 cases). 95 GCA and 98 TAA patients received biological agents. The RCTs using anti-TNF agents (infliximab, etanercept and adalimumab) did not suggest a benefit in GCA. GCA patients receiving tocilizumab, in case series, achieved remission (19 patients) and reduction of corticosteroid dose (mean difference, -16.55 mg/day (95% CI: -26.24, -6.86)). In case series, 75 patients with refractory TAA treated with infliximab discontinued CS 32% of the time. Remission was variably defined and the studies were clinically heterogeneous which precluded further analysis.<h4>Conclusion</h4>This systematic review demonstrated a weak evidence base on which to assess the effectiveness of biological treatment in LVV. Evidence from RCTs suggests that anti-TNF agents are not effective for remission or reduction of CS use. Tocilizumab and infliximab may be effective in the management of LVV and refractory TAA, respectively, although the evidence comes from case series. Future analytical studies are needed to confirm these findings.https://doi.org/10.1371/journal.pone.0115026
collection DOAJ
language English
format Article
sources DOAJ
author Mohammed Osman
Christian Pagnoux
Donna M Dryden
Dale Storie
Elaine Yacyshyn
spellingShingle Mohammed Osman
Christian Pagnoux
Donna M Dryden
Dale Storie
Elaine Yacyshyn
The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.
PLoS ONE
author_facet Mohammed Osman
Christian Pagnoux
Donna M Dryden
Dale Storie
Elaine Yacyshyn
author_sort Mohammed Osman
title The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.
title_short The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.
title_full The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.
title_fullStr The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.
title_full_unstemmed The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.
title_sort role of biological agents in the management of large vessel vasculitis (lvv): a systematic review and meta-analysis.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description <h4>Background</h4>Giant cell arteritis (GCA) and Takayasu's arteritis (TAA) are large vessel vasculitides (LVV) for which corticosteroids (CS) are the mainstay for treatment. In patients with LVV unable to tolerate CS, biological agents have been used with variable effectiveness.<h4>Objective</h4>To systematically review the effectiveness and safety of biological agents in patients with LVV.<h4>Methods</h4>We searched 5 electronic databases (inception to October 2012) and conference abstracts with no language restrictions. Two reviewers independently selected studies, extracted data and assessed methodological quality. Our protocol was registered in PROSPERO.<h4>Results</h4>We included 25 studies (3 RCTs and 22 case series with ≥2 cases). 95 GCA and 98 TAA patients received biological agents. The RCTs using anti-TNF agents (infliximab, etanercept and adalimumab) did not suggest a benefit in GCA. GCA patients receiving tocilizumab, in case series, achieved remission (19 patients) and reduction of corticosteroid dose (mean difference, -16.55 mg/day (95% CI: -26.24, -6.86)). In case series, 75 patients with refractory TAA treated with infliximab discontinued CS 32% of the time. Remission was variably defined and the studies were clinically heterogeneous which precluded further analysis.<h4>Conclusion</h4>This systematic review demonstrated a weak evidence base on which to assess the effectiveness of biological treatment in LVV. Evidence from RCTs suggests that anti-TNF agents are not effective for remission or reduction of CS use. Tocilizumab and infliximab may be effective in the management of LVV and refractory TAA, respectively, although the evidence comes from case series. Future analytical studies are needed to confirm these findings.
url https://doi.org/10.1371/journal.pone.0115026
work_keys_str_mv AT mohammedosman theroleofbiologicalagentsinthemanagementoflargevesselvasculitislvvasystematicreviewandmetaanalysis
AT christianpagnoux theroleofbiologicalagentsinthemanagementoflargevesselvasculitislvvasystematicreviewandmetaanalysis
AT donnamdryden theroleofbiologicalagentsinthemanagementoflargevesselvasculitislvvasystematicreviewandmetaanalysis
AT dalestorie theroleofbiologicalagentsinthemanagementoflargevesselvasculitislvvasystematicreviewandmetaanalysis
AT elaineyacyshyn theroleofbiologicalagentsinthemanagementoflargevesselvasculitislvvasystematicreviewandmetaanalysis
AT mohammedosman roleofbiologicalagentsinthemanagementoflargevesselvasculitislvvasystematicreviewandmetaanalysis
AT christianpagnoux roleofbiologicalagentsinthemanagementoflargevesselvasculitislvvasystematicreviewandmetaanalysis
AT donnamdryden roleofbiologicalagentsinthemanagementoflargevesselvasculitislvvasystematicreviewandmetaanalysis
AT dalestorie roleofbiologicalagentsinthemanagementoflargevesselvasculitislvvasystematicreviewandmetaanalysis
AT elaineyacyshyn roleofbiologicalagentsinthemanagementoflargevesselvasculitislvvasystematicreviewandmetaanalysis
_version_ 1714807661729415168